Misinformation and outdated beliefs about screening tests, treatment options, and effects on sexual health continue to cloud understanding about this disease.
The Columbia community gathered in the Hudson Valley for the eighth annual Velocity: Columbia’s Ride to End Cancer. This year’s event raised more than $1 million and attracted nearly 600 participants.
Columbia researchers have engineered bacteria as personalized cancer vaccines that activate the immune system to specifically seek out and destroy cancer cells.
Physician-scientist Juanma Schvartzman is a firm believer that his curiosity-driven research on cell metabolism and its influence on cell identity will offer clues for better cancer treatments.
Collaboration will investigate a system biology approach to identifying treatment options for patients with advanced gastrointestinal stromal tumors (GIST).
Columbia University researchers have created a user-friendly program that rapidly predicts which genes are implicated in an individual’s cancer and recommends treatments.
In a phase 1 study, eight out of 12 patients with relapsed and/or refractory blood cancers responded to a combination of two common chemotherapy drugs.
Dr. Drake studies the body’s immunological response to radiation therapy and how immunotherapy and radiation therapy can be used in concert to treat cancer.
Adding a new drug called olaratumab to traditional chemotherapy increased survival in sarcoma patients, researchers at Columbia University Medical Center have found.
The three-dimensional structure could help researchers develop novel therapies and diagnostic tools for diseases that are caused by a malfunction in calcium adsorption.
According to a new report published in JAMA Oncology, women with BRCA1 mutations have a higher risk of developing an aggressive type of uterine cancer.